Evidence map›Paper›PMID 25594431›Full record

ReviewAnnual review of immunology2015

TAM receptor signaling in immune homeostasis.

Carla V Rothlin, Eugenio A Carrera-Silva, Lidia Bosurgi, Sourav Ghosh

Abstract readReview
In one paragraph

Review in Annual review of immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 309 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
309citing papers in PubMed, 2 pooled it
14.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

309 citing papers in PubMed, 2 syntheses or guidelines pooled it, 503 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Observational
  20. Article

249 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Carla V RothlinDepartment of Immunobiology and.
Eugenio A Carrera-Silva
Lidia Bosurgi
Sourav Ghosh
Yale University · US

Funding

SPORE in Gastrointestinal CancerP50CA095060 · NCI · UNIVERSITY OF ARIZONA · PI GERNER, EUGENE W · 2002 to 2012
$25.3M
TAM receptor tyrosine kinases in inflammatory boweldiseaseR01AI089824 · NIAID · YALE UNIVERSITY · PI ROTHLIN, CARLA · 2010 to 2018
$3.9M
NCI NIH HHS CA95060NCI NIH HHS P50 CA095060NIAID NIH HHS R01 AI089824NIAID NIH HHS R01AI089824
6 · The paper itself

Abstract

The TAM receptor tyrosine kinases (RTKs)-TYRO3, AXL, and MERTK-together with their cognate agonists GAS6 and PROS1 play an essential role in the resolution of inflammation. Deficiencies in TAM signaling have been associated with chronic inflammatory and autoimmune diseases. Three processes regulated by TAM signaling may contribute, either independently or collectively, to immune homeostasis: the negative regulation of the innate immune response, the phagocytosis of apoptotic cells, and the restoration of vascular integrity. Recent studies have also revealed the function of TAMs in infectious diseases and cancer. Here, we review the important milestones in the discovery of these RTKs and their ligands and the studies that underscore the functional importance of this signaling pathway in physiological immune settings and disease.

Indexed as

HomeostasisSignal TransductionAnimalsDisease SusceptibilityHumansImmunityLigandsReceptor Protein-Tyrosine KinasesLigandsReceptor Protein-Tyrosine KinasesAXLGAS6MERTKPROS1TYRO3

Identifiers

PMID25594431
PMCPMC4491918
OpenAlexW2114206805

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.